INM

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. (INM) has 5 SEC Form 4 filings (34 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 17, 2026.

The most active filer is 10% Owner Vivo Opportunity, LLC with 15 filings. Insiders have net bought $1.2M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Eric A. Adams Chem.
  • Employees:13
  • HQ:Vancouver, BC, CA
  • IPO:2014-05-05

Insider Buying

$1.2M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Unique Insiders

2

in the rolling window

Market Cap

$6.1M

latest known value

Source
Purchase$2KJul 17SEC ↗
Purchase$8KJul 17SEC ↗
Purchase$23KJul 17SEC ↗
Purchase$33Jul 17SEC ↗
Purchase$924Jul 2SEC ↗
Purchase$7KJul 2SEC ↗
Purchase$2KJul 2SEC ↗
Purchase$88KJun 11SEC ↗
Purchase$57KJun 11SEC ↗
Purchase$28KJun 11SEC ↗
Purchase$25KJun 11SEC ↗
Purchase$35KJun 11SEC ↗
Purchase$12KJun 11SEC ↗
Purchase$11KJun 11SEC ↗
Purchase$86KJun 11SEC ↗
Purchase$49KJun 11SEC ↗
Purchase$722KMay 21SEC ↗

Related companies

InMed Pharmaceuticals Inc. is in the Healthcare sector.